Objectives-We compared the efficacy, safety, and cost-effectiveness of ultrasoundguided percutaneous polidocanol injection and percutaneous ethanol injection for the treatment of benign cystic and predominantly cystic thyroid nodules.
T hyroid nodules are common in clinical practice. Approximately 15% to 25% of solitary thyroid nodules are cystic or predominantly cystic, and most nodules are benign.
1,2 Percutaneous ethanol injection is recommended as the first-line treatment option for cystic thyroid nodules. 3 However, it is less effective in predominantly cystic nodules, with a high recurrence rate (26%-38.3%) than in cystic thyroid nodules. [4] [5] [6] Polidocanol is a liquid detergent sclerosant developed in 1936 as a topical and local anesthetic. It has been used as a treatment for hemorrhoidal disease, 7 venous malformations, 8 symptomatic hepatic cysts, 9 renal cysts, 10 gastric varices, 11 and digital mucous cysts. 12 With its widespread availability, ease of use, and safety profile, polidocanol may be a potential alternative to ethanol for the treatment of benign cystic and predominantly cystic thyroid nodules. Our previous research showed that ultrasound (US)-guided percutaneous polidocanol injection for benign cystic and predominantly cystic thyroid nodules is effective and safe. 13, 14 This study aimed to compare the efficacy and safety of US-guided percutaneous ethanol injection and percutaneous polidocanol injection for the treatment of benign cystic and predominantly cystic thyroid nodules.
Materials and Methods
This retrospective study was approved by the Institutional Review Board of the First Affiliated Hospital of Wenzhou Medical University. Informed consent was obtained from all patients before percutaneous ethanol or polidocanol injection of benign cystic and predominantly cystic thyroid nodules.
Seventy patients with 70 benign cystic thyroid nodules and 65 patients with 65 predominantly cystic thyroid nodules treated with percutaneous ethanol injection were enrolled retrospectively in the study from May 2010 to April 2012. Seventy-five patients with 75 benign cystic thyroid nodules and 61 patients with 61 predominantly cystic thyroid nodules treated with percutaneous polidocanol injection were enrolled in the study from May 2012 to March 2016. The same physicians on our team performed the treatment procedures and recorded the treatment results. All of the enrolled patients had the following: (1) single cystic or predominantly cystic nodules; (2) nodules with a solitary portion of less than 50%; (3) pressure symptoms or cosmetic problems; (4) no malignant or indeterminate cytologic results after US-guided fine-needle aspiration; (5) normal serum thyroid hormone levels; and (6) no malignant features on US examinations. Nodules with a solid component of less than 10% and those with a solid component of 10% to 50% were classified as cystic and predominantly cystic, respectively.
Ultrasound examinations were performed in all of the patients before the treatment and at 1, 3, 6, and 12 months after the treatment. The volume of each nodule was calculated by the following equation: volume 5 pabc/6, where a was the largest diameter, and b and c were the other mutually perpendicular diameters. 15 The changes in the volume of the nodules were evaluated by US examinations.
Before and after ethanol and polidocanol injections were administered, the patients were instructed to rate the pressure symptom score on a visual analog scale (0-10 cm) and the cosmetic grade (1, no palpable mass; 2, a palpable mass but no cosmetic problem; 3, a cosmetic problem on swallowing only; and 4, a readily detected cosmetic problem). 16 Major and minor complications were defined by the Society of Interventional Radiology. 17 Procedure-related pain was graded in 4 categories (0, no pain or mild pain similar to pain during injection; 1, pain greater than injection but not needing medication; 2, pain needing medication; and 3, injection procedure incompletely terminated because of severe pain). 16 The therapeutic success rate was defined as nodule volume reduction of greater than 50%. 4, 16 The cost was the total of clinical test, injection, and ablation costs.
Procedures
The procedures were performed in the outpatient clinic. Patients were placed in a supine position with mild neck extension. An 18-or 20-gauge needle was inserted into the cystic portion of the nodule under US guidance. The fluid was first completely aspirated. The syringe tube was then replaced with another tube containing polidocanol (Lauromacrogol; Shanxi Tianyu Pharmaceutical Co, Ltd, Xi'an, China) or ethanol while keeping the puncture needle in place. The amount of polidocanol injected was 25% to 33% of the aspirated fluid, and the maximum dose injected was 35 mL at a time. We extracted and flushed the injection 5 times to ensure that the injectate was uniformly distributed and the polidocanol remained in the cysts (Figure 1 ). Then the needle was withdrawn. Ethanol was injected slowly into the cystic space. The volume of ethanol injected corresponded to about 50% of the volume of aspirated fluid. After 10 minutes with the needle in place, the injected ethanol was removed completely, and the needle was slowly withdrawn. The patients were asked to apply pressure over the puncture site for 30 minutes. 
Statistical Analysis

Results
No significant differences in any clinical or demographic parameters were observed between the polidocanol and ethanol injection groups before the treatment (Table 1) . For the cystic nodules, 74 patients in the polidocanol group and 67 patients in the ethanol group achieved therapeutic success at the 12-month follow-up (P 5 .35; Table 2 ). For the predominantly cystic nodules, 58 patients in the polidocanol group and 55 patients in the ethanol group achieved therapeutic success at the 12-month follow-up (P 5 .05, Table 2 ).
Percutaneous polidocanol and ethanol injections resulted in significantly improved cosmetic scores (P < .001; Table 2 ) and symptom scores (P < .001; Table 2 ). However, neither the cosmetic scores (P 5 .59; P 5 .42; Table 2 ) nor the symptom scores (P 5 .32; P 5 .73; Table 2 ) in the cystic and predominantly cystic nodules were significantly different between Data are presented as mean 6 SD (range) were applicable. the groups at the last follow-up. The total cost was significantly different between the groups. The cost of ethanol injection was lower than that of polidocanol injection (P < .001; Table 2 ). The mean cystic thyroid nodule volumes 6 SDs at the US follow-up after 1, 3, 6, and 12 months were 4.470 6 5.47, 1.69 6 3.07, 0.52 6 0.58, and 0.44 6 0.78 mL in the percutaneous polidocanol injection group (P < .001; Figure 2 ) and 3.78 6 4.02, 1.62 6 1.55, 0.65 6 0.74, and 0.61 6 0.84 mL in the percutaneous ethanol injection group (P < .001; Figure 2 ), respectively. No significant difference in the reduction of the nodule volume was observed between the groups (P > .05; Figure 2 ). At the 12-month follow-up of the cystic thyroid nodules, the nodule volume reduction rates from baseline were 95.55% 6 7.90% (range, 56.26%-100%) in the polidocanol group and 94.43% 6 8.81% (range, 32.16%-100%) in the ethanol group (P 5 .816; Figure 3) .
The predominantly cystic thyroid nodule volume decreased significantly after the polidocanol and ethanol injections. The nodule volume decreased from 15.01 6 15.54 mL (range, 2.46-51.21 mL) to 2.11 6 1.67 mL (range, 0.59-13.53 mL) in the polidocanol group at the 12-month follow-up (P < .001; Figure 4 ). The nodule volume decreased from 14.52 6 14.93 mL (range, 4.98-51.57 mL) to 2.76 6 2.64 mL (range, 0.81-19.16 mL) in the ethanol group at the 12-month follow-up (P < .001; Figure 4 ). No significant differences in the predominantly cystic nodule volumes were observed between the groups at the follow-up (P > .05; Figure 4) . No significant differences in the mean volume reduction rates were observed between the polidocanol and ethanol groups at the follow-up (P > .05; Figure 5 ). The mean volume reduction rates were 83.3% 6 9.15% (range, 46.90%-96.50%) in the polidocanol group and 80.84% 6 16.22% (range, 34.00%-91.07%) in the ethanol group at the 12-month follow-up (P 5 .07; Figure 5 ).
Thirteen patients (9.56%) reported mild or moderate localized pain lasting for 1 to 5 days after the polidocanol injection, and 1 of these cases required analgesics. Thirty-five patients (25.93%) in the ethanol group reported mild or moderate localized pain with a duration of 1 to 5 days, and 2 of these cases required analgesics (P < .01). Fourteen patients (10.37%) in the ethanol group had symptoms of drunkenness, such as flushing, increased heartbeat, and nausea. 9 None of the patients in the polidocanol group had drunkenness reactions (P 5 .01). The groups did not have any major complications either during the procedure or in the follow-up period (P 5 .99).
Discussion
Percutaneous ethanol injection is minimally invasive, safe, and cost-effective. Ethanol affects the tissues by endothelial damage, which leads to the thrombosis of small vessels, which provides permanent tissue ablation and vascular occlusion. 18 However, this treatment is debatable as the first-line option for predominantly cystic thyroid nodules because of the high recurrence rate. A recent study showed that the recurrence rate was greater than 50% if the nodules had solid components of greater than 20%. 5 Side effects of ethanol for cystic thyroid nodules seem to be few. Some studies reported pain/"burning sensation" radiating to the ear or neck in 12% to 21% of the treatment sessions. 19, 20 Patients with large thyroid nodules treated with ethanol had a higher rate (71%) of pain. 21, 22 There are other side effects, Data are presented as mean 6 SD (range) were applicable.
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including transient vocal cord palsy, respiratory distress requiring emergency surgical treatment, and venous thrombosis, in sporadic cases. 19, 22 Some prospective randomized studies showed that the therapeutic efficacy of radiofrequency ablation was not superior to that of ethanol injection in cystic or predominantly cystic thyroid nodules. 15, 23 However, radiofrequency ablation can effectively control clinical problems that are incompletely resolved after ethanol injection. 5 Radiofrequency ablation has several disadvantages compared with ethanol injection, including high cost and technical difficulty. 6 As a topical and local anesthetic agent, polidocanol was introduced in Germany in 1936. 24 It is a sclerosing agent that consists of 95% hydroxypolyethoxydodecane and 5% ethyl alcohol as a preservative. It is a urethane local anesthetic that differs from the more classic ester and amide anesthetic agents by lacking an aromatic ring. Its detergent action induces rapid overhydration of cells, leading to destruction. 25 Polidocanol can be used for sclerosing varicose veins; therefore, it is a safe agent without reaspiration. Some studies showed that polidocanol was a safe and effective sclerosant for hepatic and renal cysts, with lower complication rates than those of ethanol. [26] [27] [28] Brunken et al 10 reported that 118 patients with 132 renal cysts were followed over a mean period of 25.8 months. Most of the cysts disappeared completely or remained less than 10% of the initial volume without repeated interventions associated with sclerotherapy performed with ethanol. In the literature, few studies have examined polidocanol as a sclerosing agent for thyroid nodules. Belcaro et al 29 evaluated the long-term efficacy of polidocanol for treating benign cystic nodules. After 5 years, in the group treated with the sclerosing agent, 93% of the cysts completely disappeared. At 10 years, more than 90% of the original sclerosed target cysts were not visible, and no side effects were noted. Chen et al 30 found that polidocanol was effective and safe for treatment of benign cystic thyroid nodules. Eighty-two of the 97 cysts (82.83%) achieved therapeutic success, and only 2 of 97 patients (2%) had mind pain and mild fever. Our study also showed that US-guided percutaneous polidocanol injection of benign cystic and predominantly cystic thyroid nodules was effective and safe. 13, 14 Therapeutic success of percutaneous polidocanol injection was obtained in 114 of 114 cystic nodules (100%) and 57 of 61 of predominantly cystic nodules (93.44%). A histopathologic evaluation of a rabbit model revealed that inflammation and fibrosis were significantly increased. This finding shows that polidocanol can be effectively used to treat thyroid nodules through fibrosis. 31 Our study showed that the rate of pain for the patients in the ethanol group was significantly higher than that for the patients in the polidocanol group because of polidocanol's inherent anesthetic effects. 12 After receiving the ethanol injection, 14 patients had symptoms of drunkenness, such as palpitation, dizziness, and a flushed face. None of the patients in the polidocanol group had these drunkenness reactions. Both groups had no major complications.
Our study was characterized by some limitations. Our work was a single-center retrospective nonrandomized study. Further prospective and randomized studies are needed to support our findings.
In conclusion, percutaneous ethanol and polidocanol sclerotherapy used for the management of benign cystic and predominantly cystic thyroid nodules requires minimally invasive procedures and produces minimal complications. With its simpler procedure and lower occurrence of complications, polidocanol is as effective as ethanol for the treatment of cystic and predominantly cystic thyroid nodules. Therefore, it can be used as sclerotherapy for cystic and predominantly cystic thyroid nodules. However, the cost of polidocanol injection was higher than that of ethanol injection of cystic thyroid nodules.
